• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.

作者信息

Noori Somayya, Wijnands Charissa, Langerhorst Pieter, Bonifay Vincent, Stingl Christoph, Touzeau Cyrille, Corre Jill, Perrot Aurore, Moreau Philippe, Caillon Hélène, Luider Theo M, Dejoie Thomas, Jacobs Joannes F M, van Duijn Martijn M

机构信息

Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

出版信息

Blood Cancer J. 2023 Feb 24;13(1):30. doi: 10.1038/s41408-023-00803-z.

DOI:10.1038/s41408-023-00803-z
PMID:36828828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9957984/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05bc/9957984/b15abcbc7896/41408_2023_803_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05bc/9957984/b15abcbc7896/41408_2023_803_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05bc/9957984/b15abcbc7896/41408_2023_803_Fig1_HTML.jpg

相似文献

1
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.采用靶向质谱法对骨髓瘤微小残留病进行动态监测。
Blood Cancer J. 2023 Feb 24;13(1):30. doi: 10.1038/s41408-023-00803-z.
2
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.质谱分析法与流式细胞术在检测多发性骨髓瘤微小残留病中的比较
Cancer Med. 2021 Oct;10(20):6933-6936. doi: 10.1002/cam4.4254. Epub 2021 Sep 8.
3
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.定义不可检测：多发性骨髓瘤中微小残留病评估的现状和未来明确目标。
Blood Rev. 2021 Mar;46:100732. doi: 10.1016/j.blre.2020.100732. Epub 2020 Jul 10.
4
Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease.多发性骨髓瘤中的微小残留病：基于血液的方法监测疾病的潜力。
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e34-e40. doi: 10.1016/j.clml.2021.07.032. Epub 2021 Aug 2.
5
Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.质谱法检测多发性骨髓瘤微小残留病中单克隆免疫球蛋白。
Semin Hematol. 2018 Jan;55(1):41-43. doi: 10.1053/j.seminhematol.2018.02.008. Epub 2018 Feb 26.
6
Minimal residual disease in multiple myeloma: Benefits of flow cytometry.多发性骨髓瘤中的微小残留病灶：流式细胞术的优势。
Int J Lab Hematol. 2018 Feb;40(1):12-20. doi: 10.1111/ijlh.12757. Epub 2017 Oct 23.
7
Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.异基因造血干细胞移植后多发性骨髓瘤微小残留病的监测：流式细胞术与基于聚合酶链反应的技术比较
Bone Marrow Transplant. 2008 May;41(10):913-6. doi: 10.1038/bmt.2008.14. Epub 2008 Feb 11.
8
A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.一种用于检测骨髓瘤微小残留病的单管六色流式细胞术筛查检测方法。
Leukemia. 2007 Sep;21(9):2046-9. doi: 10.1038/sj.leu.2404815. Epub 2007 Jul 26.
9
Go with the flow for monitoring response in myeloma with minimal residual disease.顺应潮流，监测多发性骨髓瘤微小残留病的反应。
Leuk Lymphoma. 2008 Feb;49(2):177-8. doi: 10.1080/10428190701824601.
10
Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?流式细胞术检测多发性骨髓瘤微小残留病灶：为何及如何检测？
Semin Hematol. 2018 Jan;55(1):4-12. doi: 10.1053/j.seminhematol.2018.02.011. Epub 2018 Mar 9.

引用本文的文献

1
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.欧洲血液学年会-欧洲骨髓瘤网络关于多发性骨髓瘤患者诊断、治疗及随访的循证指南
Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.
2
Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study.在接受自体移植后达到完全缓解并接受来那度胺维持治疗的多发性骨髓瘤患者中，通过EuroFlow下一代流式细胞术和下一代测序检测的微小残留病的预后价值：一项前瞻性比较研究。
Haematologica. 2025 Sep 1;110(9):2160-2170. doi: 10.3324/haematol.2025.287411. Epub 2025 Apr 17.
3

本文引用的文献

1
Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.多发性骨髓瘤微小残留病灶检测：血液靶向质谱与骨髓下一代测序的比较。
Clin Chem. 2021 Nov 26;67(12):1689-1698. doi: 10.1093/clinchem/hvab187.
2
Extramedullary disease in multiple myeloma.多发性骨髓瘤中的髓外疾病。
Blood Cancer J. 2021 Sep 29;11(9):161. doi: 10.1038/s41408-021-00527-y.
3
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.基于可测量残留疾病做出临床决策可改善多发性骨髓瘤的预后。
Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.多发性骨髓瘤肾脏疾病诊断与管理的最新进展
Indian J Nephrol. 2025 Jan-Feb;35(1):8-20. doi: 10.25259/ijn_491_23. Epub 2024 Jul 24.
4
Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma.在多参数质谱分析中监测M蛋白、治疗性抗体和多克隆抗体可深入了解多发性骨髓瘤患者的治疗反应动力学。
Pharmaceutics. 2025 Jan 19;17(1):135. doi: 10.3390/pharmaceutics17010135.
5
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.克隆型质谱分析方法EasyM与EuroFlow在多发性骨髓瘤微小残留病评估中的比较。
Haematologica. 2025 Mar 1;110(3):764-767. doi: 10.3324/haematol.2024.285933.
6
Improved detection of tryptic immunoglobulin variable region peptides by chromatographic and gas-phase fractionation techniques.通过色谱和气相分段技术提高胰蛋白酶免疫球蛋白可变区肽的检测。
Cell Rep Methods. 2024 Jun 17;4(6):100795. doi: 10.1016/j.crmeth.2024.100795. Epub 2024 Jun 10.
7
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.基于质谱的多发性骨髓瘤维持治疗期间外周血 M 蛋白评估。
Blood. 2024 Aug 29;144(9):955-963. doi: 10.1182/blood.2024024041.
8
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.采用超灵敏靶向质谱法和即用型校准品对多发性骨髓瘤患者的 M 蛋白进行诊断。
Clin Chem Lab Med. 2023 Oct 12;62(3):540-550. doi: 10.1515/cclm-2023-0781. Print 2024 Feb 26.
9
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.初诊多发性骨髓瘤患者真实世界未选择人群的临床结局和血清 B 细胞成熟抗原水平。
Target Oncol. 2023 Sep;18(5):735-747. doi: 10.1007/s11523-023-00990-6. Epub 2023 Sep 8.
10
Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study.基于直接质谱法的患者血清中单克隆丙种球蛋白病不确定意义的检测和抗体测序：案例研究。
J Proteome Res. 2023 Sep 1;22(9):3022-3028. doi: 10.1021/acs.jproteome.3c00330. Epub 2023 Jul 27.
J Hematol Oncol. 2021 Aug 17;14(1):126. doi: 10.1186/s13045-021-01135-w.
4
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.监测接受单克隆抗体联合治疗的多发性骨髓瘤患者的 M 蛋白：消除干扰的实验室解决方案。
Clin Chem Lab Med. 2021 Aug 16;59(12):1963-1971. doi: 10.1515/cclm-2021-0399. Print 2021 Nov 25.
5
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.骨髓瘤微小残留病灶：应用于临床护理和新药注册。
Clin Cancer Res. 2021 Oct 1;27(19):5195-5212. doi: 10.1158/1078-0432.CCR-21-1059.
6
Applying Log-Normal Peak Fitting to Parallel Reaction Monitoring Data Analysis.应用对数正态峰拟合进行平行反应监测数据分析。
J Proteome Res. 2021 Aug 6;20(8):4186-4192. doi: 10.1021/acs.jproteome.1c00371. Epub 2021 Jul 14.
7
Sensitive multiple myeloma disease monitoring by mass spectrometry.通过质谱法进行灵敏的多发性骨髓瘤疾病监测。
Blood Cancer J. 2021 Apr 29;11(4):78. doi: 10.1038/s41408-021-00473-9.
8
Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins.质谱法用于 M 蛋白的鉴定、监测和微小残留病灶检测。
Clin Chem. 2020 Mar 1;66(3):421-433. doi: 10.1093/clinchem/hvz041.
9
IgA: Structure, Function, and Developability.免疫球蛋白A：结构、功能及可开发性
Antibodies (Basel). 2019 Dec 5;8(4):57. doi: 10.3390/antib8040057.
10
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.新诊断多发性骨髓瘤研究中微小残留病灶状态作为无进展生存期替代终点的Meta 分析。
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37. doi: 10.1016/j.clml.2019.09.622. Epub 2019 Oct 9.